Haleos Labs Ltd.

₹1,327.8

33.9 (2.6%)

HALEOSLABS Share Price

Pharmaceuticals & Biotechnology

As on April 20, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 403 Cr

P/E Ratio19.96

Dividend Yield0.01 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,294.84	Bullish
10-DMA	1,290.38	Bullish
20-DMA	1,269.8	Bullish
50-DMA	1,274.62	Bullish
100-DMA	1,287.26	Bullish
200-DMA	1,229.37	Bullish

Historical Performance

1 Year

-7.5%

3 Years

137.2%

5 Years

107%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,447	3,060	3,156	3,501	2,656
Total Expenditure	2,996	2,747	2,867	3,155	2,353
Other Income	49	38	31	17	18
Operating Profit	500	350	319	363	320
Interest	88	103	69	62	46
Depreciation	150	149	108	100	79
Profit Before Tax	262	98	166	327	196
Consolidated Net Profit	201	91	115	253	136
Adjusted EPS	67	30	38	84	45

Compounded Sales Growth

10 Years:-1.8

5 Years:5.7

3 Years:-0.3

TTM:2.4

Compounded Profit Growth

10 Years:2.4

5 Years:14.6

3 Years:-4.5

TTM:17.2

Stock Price CAGR

10 Years:N/A

5 Years:15.7

3 Years:33.6

TTM:-20

Return on Equity

10 Years:N/A

5 Years:44.8

3 Years:37.9

last year:66.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	30	30	30	30	30
Total Reserves	1,935	1,738	1,656	1,492	1,262
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	359	523	731	564	590
Other Current Liabilities	367	370	425	285	254
Short Term Borrowings	505	468	301	271	202
Total Liabilities	3,990	3,948	3,984	3,644	3,070
Capital Work in Progress	4	60	9	512	383
Long Term Loans & Advances	71	59	65	75	79
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	212	237	233	376	233
Total Current Assets	1,596	1,595	1,626	1,636	1,310
Total Assets	3,990	3,948	3,984	3,644	3,070
Adjusted Book Value	650	585	558	504	427

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 19.96, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 33.6%, indicating sustained price appreciation.
The stock carries a low beta of 0.4, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹500 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹3447 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 800024.1

No. of Shares: 603 (Approx)

Performance:-20%

P/L: ₹-199975.9

NIFTY Performance: 1%

1 day Top Gainers